Onconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.2023-11-17

Onconova Therapeutics (NASDAQ:ONTX) Third Quarter 2023 ResultsKey Financial Results Net loss: US$4.74m (loss narrowed by 12% from 3Q 2022). US$0.23 loss per share (improved from US$0.26 loss in 3Q ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2384591763?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2023-11-17 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2384591763","market":"nz","top_or_hot":-1,"title":"Onconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag","media":"Simply Wall St.","content":"<div>\n<p>Onconova Therapeutics (NASDAQ:ONTX) Third Quarter 2023 ResultsKey Financial Results Net loss: US$4.74m (loss narrowed by 12% from 3Q 2022). US$0.23 loss per share (improved from US$0.26 loss in 3Q ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ontx/onconova-therapeutics/news/onconova-therapeutics-third-quarter-2023-earnings-eps-beats\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-17 19:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ontx/onconova-therapeutics/news/onconova-therapeutics-third-quarter-2023-earnings-eps-beats><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Onconova Therapeutics (NASDAQ:ONTX) Third Quarter 2023 ResultsKey Financial Results Net loss: US$4.74m (loss narrowed by 12% from 3Q 2022). US$0.23 loss per share (improved from US$0.26 loss in 3Q ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ontx/onconova-therapeutics/news/onconova-therapeutics-third-quarter-2023-earnings-eps-beats\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ontx/onconova-therapeutics/news/onconova-therapeutics-third-quarter-2023-earnings-eps-beats","article_id":"2384591763","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2384591763","pubTimestamp":1700220755,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Onconova Therapeutics ( NASDAQ:ONTX ) Third Quarter 2023 Results Key Financial Results Net loss: US$4.74m (loss...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Onconova Therapeutics 2023年第三季度收益：每股收益超出预期，收入滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONTX":1},"content_text":"Onconova Therapeutics (NASDAQ:ONTX) Third Quarter 2023 ResultsKey Financial Results Net loss: US$4.74m (loss narrowed by 12% from 3Q 2022). US$0.23 loss per share (improved from US$0.26 loss in 3Q 2022).  NasdaqCM:ONTX Earnings and Revenue History November 17th 2023 All figures shown in the chart above are for the trailing 12 month (TTM) period Onconova Therapeutics EPS Beats Expectations, Revenues Fall Short  Revenue missed analyst estimates by 18%.  Earnings per share (EPS) exceeded analyst estimates by 21%.      Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.    Performance of the American Pharmaceuticals industry.  The company's shares are down 1.6% from a week ago.   Risk Analysis Before we wrap up, we've discovered 4 warning signs for Onconova Therapeutics (2 shouldn't be ignored!) that you should be aware of. What are the risks and opportunities for Onconova Therapeutics?NasdaqCM:ONTXOnconova TherapeuticsOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.Show moreView Full AnalysisRewardsRevenue is forecast to grow 13.17% per yearRisksEarnings are forecast to decline by an average of 27% per year for the next 3 yearsMakes less than USD$1m in revenue ($226K)Does not have a meaningful market cap ($13M)Currently unprofitable and not forecast to become profitable over the next 3 yearsView all Risks and RewardsShare PriceMarket Cap1Y ReturnView Company ReportFurther research onOnconova TherapeuticsValuationFinancial HealthInsider TradingManagement TeamHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2384591763"}